Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Merselis James D
 2. Date of Event Requiring Statement (Month/Day/Year)
06/13/2005		 3. Issuer Name and Ticker or Trading Symbol
HEMOSENSE INC [HEMO]
(Last)
(First)
(Middle)
C/O HEMOSENSE, INC., 651 RIVER OAKS PKWY		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President, CEO
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

SAN JOSE, CA 95134		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy)   (1)(4) 06/05/2012 Common Stock 145,000 $ 0.8 D  
Employee Stock Option (right to buy)   (2) 07/11/2013 Common Stock 24,125 $ 0.8 D  
Employee Stock Option (right to buy)   (3)(4) 02/17/2015 Common Stock 113,750 $ 0.8 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Merselis James D
C/O HEMOSENSE, INC.
651 RIVER OAKS PKWY
SAN JOSE, CA 95134		   X   X   President, CEO  

Signatures

/s/ James D. Merselis 06/13/2005
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This option vests and becomes exercisable as to (i) 14,500 shares immediately, (ii) 21,750 shares upon the achievement of certain milestones and (iii) 1/42nd of the remaining 108,750 shares on the 1st day of each month beginning on December 3, 2002.
(2) Immediately.
(3) This option vests and becomes exercisable as to 25% of the shares on February 17, 2006 and 1/48th of the shares on the 1st day of each month thereafter.
(4) This option will also immediately vest as to 20% of the shares upon the effective date of the issuer's Registration Statement on Form S-1 estimated to be on or around June 13, 2005.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.